ArticleTranslational pediatrics2025
Clinical analysis of 73 children with anti-N-methyl-D-aspartic receptor (NMDAR) encephalitis.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: Clinical analysis of 73 children with anti-N-methyl-D-aspartic receptor (NMDAR) encephalitis.Translational pediatrics · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-N-methyl-D-aspartic receptor (NMDAR) encephalitis is a severe neurological condition often seen in pediatric patients. Early identification of clinical characteristics and prognostic risk factors is essential for optimizing diagnosis and treatment. This study aimed to systematically assess the clinical features and treatment outcomes of pediatric anti-NMDAR encephalitis and to identify independent prognostic risk factors for poor outcomes. Methods: This retrospective study included 73 pediatric patients with anti-NMDAR encephalitis. Demographic information, clinical presentation, diagnostic information [magnetic resonance imaging (MRI) and electroencephalography (EEG)], treatments received, and follow-up data were reviewed and analyzed. Based on modified Rankin Scale (mRS) scores at 2-month post-treatment follow-up, patients were stratified into favorable prognosis (mRS ≤2) and poor prognosis (mRS >2) groups. Comparative analyses of clinical parameters were performed using independent samples t-tests for continuous variables and the Pearson Chi-squared test for categorical variables. Statistically significant variables from univariate analyses were subsequently entered into a multivariate logistic regression model to identify independent prognostic factors. Results: Among the cohort, 51 patients (69.86%) achieved favorable outcomes, while 22 patients (30.14%) exhibited poor prognosis. Significant intergroup differences emerged in peak mRS scores (t=5.32, P<0.001), presence of abnormal MRI findings (χ Conclusions: Our findings demonstrate that elevated peak disease severity (as quantified by mRS) and structural brain abnormalities on MRI represent significant prognostic indicators in pediatric anti-NMDAR encephalitis. These parameters should be incorporated into clinical risk stratification models to guide therapeutic decision-making and prognostic counselling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.